How dependent is India on Plasma Derived Therapeutics imports?

India imports $0.30 bn, mostly from USA. Its Critical Manufacturing Dependency Index is 65.04/100 (High), with a localisation potential of 58.

Plasma Derived Therapeutics

High dependencyBuild-nowPharmaceuticals & APIsReasoned estimateHS 3002.10

$0.30 bnAnnual import

30%Indian capability

4,766Supplier concentration (HHI)

₹3,761 crTo localise

Why India imports it. Reasoned estimate: India has limited domestic capacity for plasma derived therapeutics; sector trade patterns indicate continued import reliance.

Why it matters. Strategic dependency within pharma value chain; affects downstream manufacturing competitiveness.

Can India localise it? Partial

Where it comes from. USA (56%), Germany (31%), Japan (13%).

Scorecard

The ten indices

CMDI 65.04Dependency

LPI 58Localisation potential

IAI 66.25Investment attractiveness

SRI 64.9Supply risk

SCI 51.5Supply-chain complexity

TRI 43.75Technology readiness

IMI 66.5Industrial multiplier

NSRI 57.25National-security relevance

EPI 65.25Export potential

ICGI 58.47Capability gap

Intelligence

Related signals

Sources

Primary references

pharmaceuticals.gov.in ↗

Confidence: Reasoned estimate. Reasoned estimate derived from sector trade patterns and HS code classification; specific company/number values are modelled. Part of Techadyant Labs' Critical Manufacturing Dependencies (Edition I).